(MedPage Today) — The FDA halted patient enrollment in a phase III trial of evenamide in treatment-resistant schizophrenia following the sudden death of a participant, Newron Pharmaceuticals said.
Magnetic seizure therapy achieved similar remission…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
